Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesClinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology
Current Drug Targets, 10/23/09
Gualberto A et al. – Early clinical trials reveal an acceptable safety profile together with pharmacodynamic evidence of receptor targeting. Instances of single–agent activity during phase I evaluations have been well documented and a recently reported randomized phase II study indicates that co–administration of an anti–IGF–IR antibody with chemotherapy improves objective response rate and progression–free survival in non–small cell lung cancer patients. These early results support ongoing research across a broad range of cancer indications.
Related Articles
Accuracy of reporting current medications by cancer patients presenting to an emergency center
Supportive Care in Cancer, 11/11/09
Relevance Score: 68%
Safety Profile of IBD: Lymphoma Risks
Gastroenterology Clinics of North America, 11/16/09
Relevance Score: 66%
Hepato-biliary late effects in survivors of childhood and adolescent cancer: A report from the Children's Oncology Group
Pediatric Blood & Cancer, 11/12/09
Relevance Score: 66%
Code Status Documentation in the Outpatient Electronic Medical Records of Patients with Metastatic Cancer
Journal of General Internal Medicine, 11/10/09
Relevance Score: 66%
Rates of Skin Cancer Screening and Prevention Counseling by US Medical Residents
Archives of Dermatology, 10/21/09
Relevance Score: 66%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Drug Approval Summary: Bevacizumab (Avastin) as Treatment of Recurrent Glioblastoma Multiforme
The Oncologist, 12/02/09
Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09
Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors
Clinical Cancer Research, 12/01/09
Sponsor
Article Search
Sponsor